Recent Advances in Obesity Pharmacotherapy
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dynamics of fat cell turnover in humans
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., et al. (2008) · Nature · doi:10.1038/nature06902 · Cited by 2,357 · cited 1×
“Finally, a recent article determined that adipocyte number in human adipose tissue is determined since early adulthood, as a consequence of a precise balance between new adipocites generation and adipocite death [97].”
BackgroundWeight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583 · cited 1×
“Studies in genetically manipulated mice showed that elimination of -MSH, overexpression of AgRP or MC-4 receptor knockout resulted in obesity [80].”
BackgroundCause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542 · cited 1×
“It is associated with multiple coexisting conditions (such as hypertension, glucose intolerance, dyslipidemia, and obstructive sleep apnea), and an increased risk of death from cardiovascular disease, diabetes, kidney disease, and obesity-related cancers (colon, breast, esophageal, uterine, ovarian, kidney, and pancre…”
BackgroundEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · cited 6×
“Most of the drug and its active metabolites are renally excreted [13].”
BackgroundInfluential
Cited by
Possible anti-obesity therapeutics from nature--a review
Yun, J. W. (2010) · Phytochemistry · doi:10.1016/j.phytochem.2010.07.011 · Cited by 619
on behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
SIMÃO, A. A., MARQUES, T. R., MARCUSSI, S., & CORRÊA, A. D. (2017) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201720160067 · Cited by 44
“…cost of drugs traditionally used in the treatment of this disease, the potential of natural products for treatment of obesity have been widely explored, and they may be a viable alternative for future development of more effective and safe anti-obesity drugs (Park et al. 2005, Mayer et al. 2009).”
Background
Metadata
- Authors
- Mayer, M., Hocht, C., Puyo, A., & Taira, C.
- Venue
- Current Clinical Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-01-01
- Volume
- 4
- Issue
- 1
- Pages
- 53-61
- ISSN
- 1574-8847 (ISSN-L)
- OpenAlex
- W2121195629
- Cited by
- 107
- References
- 14
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in Obesity Pharmacotherapy. https://app.cochat.ai/papers/10.2174/157488409787236128
- The paper
- Mayer, M., Hocht, C., Puyo, A., & Taira, C. (2009). Recent Advances in Obesity Pharmacotherapy. Current Clinical Pharmacology. https://doi.org/10.2174/157488409787236128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.